Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon And Viatris Get CRL From FDA On Insulin Aspart

Biosimilar Rival To NovoLog Already Approved In Europe As Kixelle

Executive Summary

Viatris and partner Biocon have suffered a setback over their proposed insulin aspart biosimilar rival to NovoLog in the US, after the FDA issued a CRL relating to the filing.

You may also be interested in...



Keeping Track: Idorsia’s Quviviq Is FDA’s First Novel Approval Of 2022; AbbVie’s Rinvoq Gains Eczema Claim

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Viatris Dishes On Insulin Aspart Biosimilar As Key Date Passes

Viatris has provided an update on its biosimilar pipeline, covering assets including insulin glargine, insulin aspart, aflibercept and bevacizumab, as part of its second quarter strategic update.

Viatris Wins Landmark First US Interchangeability Designation For Semglee

Viatris has revealed its commercial strategy for its Semglee insulin glargine biosimilar in the US after winning a landmark first designation of interchangeability for the product from the FDA that will allow pharmacy-level substitution with a year of exclusivity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel